Evidence map›Paper›PMID 30410343›Full record

ReviewVascular health and risk management2018

Role of androgens in cardiovascular pathology.

Dimitry A Chistiakov, Veronika A Myasoedova, Alexandra A Melnichenko, Andrey V Grechko, Alexander N Orekhov

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Vascular health and risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04710186 (The Influence of Androgen Receptor, Insulin Like Growth Factor 1 Receptor, and Insulin Receptor in Male Patients With Peripheral Artery Disease), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04710186 unknown statusnot on this map

The Influence of Androgen Receptor, Insulin Like Growth Factor 1 Receptor, and Insulin Receptor in Male Patients With Peripheral Artery Disease

TypeobservationalSponsorUniversity of CatanzaroRan2018 to 2021Enrolled30ConditionsAndrogen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect inArmsarterial reconstructive open surgery
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Dimitry A ChistiakovDepartment of Neurochemistry, Division of Basic and Applied Neurobiology, Serbsky Federal Medical Research Center of Psychiatry and Narcology, Moscow, Russia.
Veronika A MyasoedovaLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia, a.h.opexob@gmail.com.
Alexandra A MelnichenkoLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia, a.h.opexob@gmail.com.
Andrey V GrechkoFederal Scientific Clinical Center for Resuscitation and Rehabilitation, Moscow, Russia.
Alexander N OrekhovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia, a.h.opexob@gmail.com.
Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RUFederal Medical Research Centre for Psychiatry and Narcology · RUV.A. Negovsky Scientific Research Institute of General Reanimatology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular effects of android hormones in normal and pathological conditions can lead to either positive or negative effects. The reason for this variation is unknown, but may be influenced by gender-specific effects of androids, heterogeneity of the vascular endothelium, differential expression of the androgen receptor in endothelial cells (ECs) and route of androgen administration. Generally, androgenic hormones are beneficial for ECs because these hormones induce nitric oxide production, proliferation, motility, and growth of ECs and inhibit inflammatory activation and induction of procoagulant, and adhesive properties in ECs. This indeed prevents endothelial dysfunction, an essential initial step in the development of vascular pathologies, including atherosclerosis. However, androgens can also activate endothelial production of some vasoconstrictors, which can have detrimental effects on the vascular endothelium. Androgens also activate proliferation, migration, and recruitment of endothelial progenitor cells (EPCs), thereby contributing to vascular repair and restoration of the endothelial layer. In this paper, we consider effects of androgen hormones on EC and EPC function in physiological and pathological conditions.

Indexed as

AndrogensAnimalsCardiovascular DiseasesEndothelial CellsEndothelial Progenitor CellsEndothelium, VascularHormone Replacement TherapyHumansMyocardiumSignal TransductionTestosteroneAndrogensTestosteroneandrogensatherosclerosiscardiovascular disordersrisk factorstestosterone therapy

Identifiers

PMID30410343
PMCPMC6198881
OpenAlexW2897361985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.